MacroGenics | MGNX - Заемный капитал





Заемный капитал Изменить Дата
AbbVie USD 64.53B 5.59B 2026-03
Amgen USD 51.86B 27M 2026-06
AstraZeneca USD 26.01B 46M 2026-06
Biogen USD 7.29B 1B 2026-06
Bristol-Myers Squibb USD 42.09B 59M 2026-06
Daiichi Sankyo JPY 500B 199.92B 2026-06
Eli Lilly USD 47.86B 8.49B 2026-06
Genmab DKK 4.96B 28M 2026-06
Geron USD 120.13M 298K 2026-06
Gilead Sciences USD 20.86B 1.27B 2026-03
J&J USD 37.34B 183M 2026-06
Karyopharm Therapeutics USD 264.49M 13.73M 2026-03
MacroGenics USD 68.71M 1.29M 2026-03
Merck USD 51.08B 4.41B 2026-06
Pfizer USD 60.5B 70M 2026-06
Puma Biotechnology USD 10.87M 222K 2025-06
Regeneron Pharmaceuticals USD 1.99B 400K 2026-06
Roche Holding CHF 25.22B 2.21B 2026-06
Xencor USD 77.54M 4.59M 2026-06